摘要
目的探讨曲普瑞林联合多西紫杉醇治疗晚期前列腺癌的临床效果。方法选取我院2016年1月至2016年12月收治的晚期前列腺癌患者共48例作为研究对象,按照数字法随机分为对照组和观察组,对照组给予曲普瑞林治疗,观察组给予曲普瑞林联合多西紫杉醇治疗,对比两组在治疗后的临床疗效、不良反应发生情况,治疗前后QLQ-C30评分(生存质量测定量表)、血清睾酮水平以及血清前列腺特异性抗原(PSA)变化情况等。结果经治疗后,观察组治疗有效率明显高于对照组(P<0.05),观察组不良反应发生率明显低于对照组(P<0.05),观察组QLQ-C30评分明显高于对照组(P<0.05),观察组的血清睾酮水平明显低于对照组(P<0.05),观察组PSA明显低于对照组(P<0.05)。结论曲普瑞林联合多西紫杉醇治疗晚期前列腺癌的临床疗效显著,安全性较高,对患者健康恢复具有积极作用,值得在临床上进一步推广应用。
Objective To explore the clinical effect of combination therapy with triptorelin and docetaxel in the treatment of advanced prostate cancer. Methods A total of 48 patients with advanced prostate cancer were selected as the research subjects in our hospital from January 2016 to December 2016.According to the digital table method,they were randomly divided into the control group and the observation group.The control group was treated with Triptorelin,and the observation group was treated with Triptorelin and docetaxel.After treatment,the clinical efficacy,the incidence of adverse reactions,the changes of QLQ-C30 score (quality of life scale),serum testosterone level,and the changes of serum prostate specific antigen (PSA) were observed before and after treatment. Results After treatment,the effective rate of the patients in observation group was significantly higher than that of the control group ( P <0.05);the incidence of adverse reactions in observation group was significantly lower than that of control group ( P <0.05).After treatment,the QLQ-C30 evaluation score in the observation group was higher than that in control group( P <0.05);the serum testosterone levels of the patients in the observation group were significantly less than that of control group ( P <0.05);the change of PSA in the observation group was significantly lower than that of control group ( P <0.05). Conclusion Triptorelin combined with docetaxel in the treatment of advanced prostate cancer has a significant clinical effect,high safety and positive effect on the recovery of patients’ health,and it is worthy of further clinical application.
作者
白晓黎
陈宏伟
BAI Xiao-li;CHEN Hong-wei(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471003,China;Department of Gastroenterology,Luoyang Central Hospital Affiliated toZhengzhou University,Luoyang 471000,China)
出处
《河南科技大学学报(医学版)》
2019年第2期127-129,共3页
Journal of Henan University of Science & Technology:Medical Science
关键词
前列腺癌
曲普瑞林
多西紫杉醇
临床疗效
advanced prostate cancer
triptorelin
docetaxel
clinical efficacy